AUTHORS
Po Yee Mak, Vishal Sahu, PhD2, Lauren Ostermann3, Kazuharu Kamachi, MD, PhD4, Yuki Nishida, MD, PhD5, Jo Ishizawa, MD, PhD6, Tomasz Tomczyk7, Agata Sniezewska8, Pawel Dobrzanski, PhD9, Michael Cardone, PhD10, Michal Walczak11, Abhishek Maiti, MBBS12, Michael Andreeff, MD, PhD13, Bing Z Carter, PhD14
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 Captor Therapeutics, Wroclaw, Poland
8 Captor Therapeutics, Wroclaw, Poland
9 Captor Therapeutics, Wroclaw, Poland
10 Europics Pharmaceuticals, Cambridge, United States
11 Captor Therapeutics, Wroclaw, Poland
12 The University of Texas MD Anderson Cancer Center, Houston, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Although BCL-2 inhibitor venetoclax (VEN)/hypomethylating agent combinations induce high remission rates in AML, the majority of patients relapse. Activation of oncogenic signaling pathways that stabilize antiapoptotic MCL-1 and TP53 mutations-mediated downregulation of pro-apoptotic proteins are among the main resistance mechanisms. We reported that MCL-1 not only directly protects cells from apoptosis but also regulates metabolic activities in AML (Carter et al., Haematologica 2022). Several MCL-1 inhibitors have been developed but unfortunately have not advanced in AML due to putative cardiotoxicity. CT-03p, a cereblon-based MCL-1 bifunctional degrader (Captor Therapeutics) was found to be cardio-safe in vivo as determined by troponin I and D analyses and histopathological examination, even at doses exceeding the Degradation Dose 50 by >100 times. In contrast to traditional inhibitors, which cause a lasting accumulation and phosphorylation (Thr163) of MCL-1 resulting in toxicity in healthy cells, CT-03p targeted MCL-1 degradation induces only a transient knockdown of the protein. This selective mechanism successfully triggers apoptosis in cancer cells while sparing unprimed, healthy tissues. We investigated the therapeutic potential of CT-03p in AML cells and stem/progenitor cells including TP53-mutant and VEN-resistant models.
CT-03p induced robust apoptosis in both parental (sensitive) and VEN resistant (VEN-R) MV4-11 cells, with an increased induction of cell death in VEN-R MV4-11 cells and was highly synergistic when combined with VEN (Bliss Synergy Score >10). Mechanistically, CT-03p effectively decreased MCL-1 protein levels and disrupted MCL-1/BIM interactions in both cell types, but more so in VEN-R cells which overexpress MCL-1. The disrupted MCL-1/BIM interactions are detected using an MCL-1/BIM dimer-specific antibody (PRIMABS-Dx). CT-03p decreased leukemia burden in vivo in MV4-11 xenografts, which was synergistically enhanced by VEN as determined by in vivo bioluminescence imaging. In MV4-11 VEN-R xenografts, CT-03p alone or CT-03p/VEN were highly effective in decreasing leukemia burden to >90% (experiment ongoing).
To assess the impact of TP53 status on CT-03p activity, we treated TP53 isogenic Molm13 cells with CT-03p.TP53 deficient cells were less sensitive to CT-03p compared to wild-type (WT) controls. Exploiting a targetable TP53-Y220C mutation model, the conversion of Y220C-p53 into WT-p53 conformation by the p53-Y220C reactivator rezatapopt (Carter, Blood 2025) enhanced activity of CT-03p in TP53-Y220C Molm13 cells, supporting the notion that refolding of mutant p53 into WT conformation sensitizes TP53-mutant cells to inhibition of antiapoptotic BCL-2 family proteins. Furthermore, combinations of CT-03p with VEN
synergistically induced apoptosis in AML cell lines intrinsically resistant to CT-03p or VEN, demonstrating synergism of concomitant targeting of both BCL-2 and MCL-1. CT-03p and VEN combinations synergistically induced cell death in AML blast cells and/or in CD34+, CD34+CD38+/CD34+CD38-, or GPR56+ stem/progenitor cells from patients with AML, including those with TP53 mutations (Bliss Synergy Score >10).
To separate the antiapoptotic from metabolic functions of MCL-1, we investigated the effects on BAX/BAK double knockout OCI-AML3 cells. CT-03p decreased MCL-1 in both control and the knockout cells, and induced cell death and suppressed OXPHOS and fatty acid oxidation (FAO) in control OCI-AML3, while inducing no cell death but similar levels of OXPHOS and FAO inhibition in the BAX/BAK knockout OCI-AML3 cells compared to controls, suggesting that the inhibition of OXPHOS and FAO is independent of apoptosis.
Conclusions: The MCL-1 degrader CT-03p decreases MCL-1 levels and the interactions of MCL-1/BIM, exerts antileukemia activity by inducing apoptosis and also suppressing metabolic activities independent of apoptosis. Combination with VEN synergistically enhances CT-03p activities in cells resistant to VEN, CT-03p, or both and in TP53-mutant AML cells and stem/progenitor cells, presumably through synergistical activation of BAX (Carter et al., Haematologica 2022). The efficacy of MCL-1 degrader CT-03p and its lack of cardiotoxicity warrants future development of this agent.
DISCLOSURES
Bing Z Carter, PhD: SillaJen - Research Funding; AmMax - Research Funding; Repare Therapeutics - Research Funding; Ona Therapeutics - Research Funding; AmMax - Consultancy (Includes expert testimony)